What are Corvus Pharmaceuticals's total assets?

Corvus Pharmaceuticals (CRVS) holds $253.2M in total assets, up 326.0% year over year.

How much debt does Corvus Pharmaceuticals have?

Corvus Pharmaceuticals carries $834.0K in total debt against $240.7M of shareholders' equity, a debt-to-equity ratio of 0.00.

How much cash does Corvus Pharmaceuticals have?

Corvus Pharmaceuticals holds $40.1M in cash and equivalents.

Can Corvus Pharmaceuticals cover its short-term obligations?

Its current ratio is 19.81 — current assets exceed current liabilities.

Where does Corvus Pharmaceuticals's balance sheet data come from?

Every line is extracted from Corvus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Corvus Pharmaceuticals CRVS Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$4.58M-47.6%	$8.74M-30.7%	$12.62M-4.1%	$13.16M-79.3%
Short-term investments	$52.17M+20.7%	$43.22M—	——	——
Accounts receivable, net	$37K-50.7%	$75K+188%	$26K-95.6%	$588K+16.0%
Prepaid expenses and other current assets	$1.43M-39.7%	$2.37M+203%	$781K+1.0%	$773K-42.9%
Total current assets	$58.21M+7.0%	$54.41M+94.6%	$27.96M-36.0%	$43.66M-38.8%
Property and equipment, net	$220K+45.7%	$151K-36.0%	$236K-33.1%	$353K-21.7%
Operating lease right-of-use assets	$839K-28.7%	$1.18M+2.4%	$1.15M-48.2%	$2.22M-30.5%
Other non-current assets	$855K+35.3%	$632K+610%	$89K-31.0%	$129K-45.3%
Equity method investments	$10.99M-12.4%	$12.54M-22.2%	$16.12M-26.3%	$21.88M-36.2%
Total assets	$71.12M+3.2%	$68.91M+51.3%	$45.55M-33.2%	$68.24M-37.7%
Accounts payable	$2.49M-3.5%	$2.58M+69.3%	$1.53M-22.8%	$1.98M+26.3%
Accrued expenses	$6.49M+74.1%	$3.73M-6.2%	$3.97M—	——
Operating lease liabilities, current	$403K+118%	$185K-86.5%	$1.37M+11.9%	$1.23M+17.4%
Total current liabilities	$9.38M-73.5%	$35.4M+415%	$6.87M-36.1%	$10.75M+10.9%
Operating lease liabilities, non-current	$534K-43.0%	$937K—	——	$1.37M-47.2%
Total liabilities	$9.91M-72.7%	$36.34M+429%	$6.87M-43.3%	$12.13M-1.4%
Preferred stock	——	$0—	$0—	——
Common stock	$7K0.0%	$7K+40.0%	$5K0.0%	$5K0.0%
Additional paid-in capital	$474.39M+10.1%	$430.86M+15.1%	$374.36M+2.7%	$364.36M+0.7%
Retained earnings	-$412.29M-3.8%	-$397.01M-18.6%	-$334.72M-8.8%	-$307.69M-15.5%
Accumulated other comprehensive income (loss)	-$896K+30.4%	-$1.29M-33.2%	-$967K-71.8%	-$563K-130%
Total stockholders' equity	$61.21M+87.9%	$32.57M-15.8%	$38.68M-31.1%	$56.12M-42.2%
Total liabilities and stockholders' equity	$71.12M+3.2%	$68.91M+51.3%	$45.55M-33.2%	$68.24M-37.7%
Available For Sale Securities Debt Securities Current	$52.17M+20.7%	$43.22M—	——	——
Deferred Tax Assets and Other Non-Current Assets	$855K+35.3%	$632K+610%	$89K-31.0%	$129K-45.3%
Net Investment in Lease	$839K-28.7%	$1.18M+2.4%	$1.15M-48.2%	$2.22M-30.5%
Operating lease right-of-use assets	$839K-28.7%	$1.18M+2.4%	$1.15M-48.2%	$2.22M-30.5%
Other non-current assets	$855K+35.3%	$632K+610%	$89K-31.0%	$129K-45.3%
Operating Lease Right-of-Use Assets in Other Assets	$839K-28.7%	$1.18M+2.4%	$1.15M-48.2%	$2.22M-30.5%
Software and Technology Licenses, Net	$855K+35.3%	$632K+610%	$89K-31.0%	$129K-45.3%
Other Commercial Liabilities	$6.49M+74.1%	$3.73M-6.2%	$3.97M—	——
Accrued Liabilities, Current	$6.49M+74.1%	$3.73M-6.2%	$3.97M—	——
Total debt	$937K-16.5%	$1.12M-18.3%	$1.37M-47.2%	$2.6M-28.7%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$7K0.0%	$7K+40.0%	$5K0.0%	$5K0.0%
Equity method investments (Note 11)	$10.99M-12.4%	$12.54M-22.2%	$16.12M-26.3%	$21.88M-36.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Corvus Pharmaceuticals's total assets?: Corvus Pharmaceuticals (CRVS) holds $253.2M in total assets, up 326.0% year over year.
How much debt does Corvus Pharmaceuticals have?: Corvus Pharmaceuticals carries $834.0K in total debt against $240.7M of shareholders' equity, a debt-to-equity ratio of 0.00.
How much cash does Corvus Pharmaceuticals have?: Corvus Pharmaceuticals holds $40.1M in cash and equivalents.
Can Corvus Pharmaceuticals cover its short-term obligations?: Its current ratio is 19.81 — current assets exceed current liabilities.
Where does Corvus Pharmaceuticals's balance sheet data come from?: Every line is extracted from Corvus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.